Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer

Download slides, review a text module, and read an expert commentary on the rationale and clinical development of therapies targeting DLL3 for patients with small-cell lung cancer

Share

Program Content

Activities

DLL3 in SCLC: Module
Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 12, 2023

Expires: April 11, 2024

Activities

DLL3 in SCLC: Slides
Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 12, 2023

Activities

DLL3 in SCLC
DLL3: Bringing Bispecific Therapy to SCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This activity is supported by educational funding provided by

Amgen